RXST (RxSight) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RXST RxSight Inc RXST
65 GF Score
Price $7.09
GF Value $25.89
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is RxSight 5-Year EBITDA Growth Rate?

RxSight RXST +0.43% 65 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates RXST with a GF Score™ of 65/100 and a GF Value™ of $25.89 (Possible Value Trap). The stock has 5 warning signs investors should review.

RxSight's EBITDA per Share for the three months ended in Jun. 2026 was $-0.27.

During the past 3 years, the average EBITDA Per Share Growth Rate was 25.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of RxSight was 41.20% per year. The lowest was 25.30% per year. And the median was 33.25% per year.

RxSight  (NAS:RXST) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

RxSight 5-Year EBITDA Growth Rate Related Terms

RXST vs INFU, SENS, LUCD: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, RxSight's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RxSight 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RxSight's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where RxSight's 5-Year EBITDA Growth Rate falls into.


RXST
65GF Score
RxSight Inc RXST
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RxSight 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
RxSight (RXST) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for RxSight and its competitors.
Is RxSight's 5-Year EBITDA Growth Rate too high?
RxSight's current 5-Year EBITDA Growth Rate is 0.00%. Overall, RxSight has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RxSight's 5-Year EBITDA Growth Rate compare to INFU and SENS?
RxSight's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for RxSight and its competitors. RxSight's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RxSight stock overvalued right now?
Based on GuruFocus' analysis, RxSight (RXST) is currently considered Possible Value Trap. The stock's GF Value™ is $25.89, compared to a current price of $7.09 — trading 72.6% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. RxSight's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For RxSight (RXST), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RxSight (RXST) Overvalued in 2026?

Based on GuruFocus' analysis, RxSight stock appears to be undervalued. The current stock price of $7.09 is trading 72.6% below its estimated GF Value™ of $25.89. GuruFocus considers RxSight to be Possible Value Trap.

Key valuation signals for RXST:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $25.89 vs. price of $7.09 (72.6% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the RXST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RxSight Business Description

Address 100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
65GF Score

Get the complete analysis for RXST

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.09
Price
$25.89
GF Value